Royalty Pharma plc (RPRX)
Healthcare • Biotechnology
StockNasdaqGSUnited StatesGB00BMVP7Y09
Kyvero is an independent information site. It is not affiliated with, endorsed by or sponsored by Royalty Pharma plc, and has no access to any account you may have with it. The name and the logo belong to their owners.
Price history
Daily prices in USD. Dividends, results and news are marked on the day they happened; click a day to see them.
Updated 13 Nov 2026 16:30. Information, not advice. Showing the last 12 months. Create a free account to see the whole history
Results
Earnings per share: estimate and reported
Estimate Reported: beat Reported: miss In line
Quarterly results
| Date | EPS estimate | EPS reported | Surprise | Result |
|---|---|---|---|---|
| 10 Feb 2027 08:00 | 1.57 | — | — | Upcoming |
| 04 Nov 2026 07:00 | 1.18 | 1.21 | +2.4% | Beat |
| 05 Aug 2026 09:00 | 1.27 | 1.32 | +3.9% | Beat |
| 06 May 2026 07:00 | 1.18 | 1.30 | +9.4% | Beat |
| 11 Feb 2026 07:00 | 1.33 | 1.47 | +10.0% | Beat |
| 05 Nov 2025 07:00 | 1.04 | 1.17 | +12.5% | Beat |
| 06 Aug 2025 07:00 | 1.03 | 1.14 | +10.5% | Beat |
| 08 May 2025 07:00 | 0.95 | 1.06 | +10.8% | Beat |
| 11 Feb 2025 07:00 | 1.05 | 1.15 | +9.2% | Beat |
| 06 Nov 2024 07:00 | 0.93 | 1.04 | +12.1% | Beat |
| 08 Aug 2024 07:00 | 0.97 | 0.96 | -0.4% | In line |
| 09 May 2024 09:00 | 0.98 | 0.98 | -0.4% | In line |
| 15 Feb 2024 09:00 | 1.00 | 1.52 | +51.7% | Beat |
| 08 Nov 2023 09:00 | 0.77 | 0.79 | +2.6% | Beat |
| 08 Aug 2023 07:00 | 0.81 | 0.84 | +4.7% | Beat |
| 09 May 2023 07:00 | 1.27 | 1.60 | +25.9% | Beat |
| 15 Feb 2023 07:00 | 1.46 | 1.56 | +6.5% | Beat |
| 08 Nov 2022 07:00 | 0.71 | 0.73 | +2.0% | Beat |
| 04 Aug 2022 07:00 | 0.78 | 0.79 | +1.4% | Beat |
| 05 May 2022 07:00 | 0.72 | 0.60 | -15.9% | Miss |
| 15 Feb 2022 07:00 | 0.78 | 0.80 | +3.7% | Beat |
| 10 Nov 2021 07:00 | 0.70 | 0.73 | +4.4% | Beat |
| 11 Aug 2021 09:00 | 0.71 | 0.71 | +0.2% | In line |
| 11 May 2021 07:00 | 0.65 | 0.67 | +3.7% | Beat |
| 17 Feb 2021 07:00 | 0.70 | 0.70 | -0.7% | In line |
| 10 Nov 2020 17:00 | 0.59 | 0.65 | +10.1% | Beat |
| 12 Aug 2020 07:00 | 0.60 | 0.61 | +0.9% | In line |
Annual results · USD
| Year | Revenue | Change | Net income | Net margin | EPS | EPS change | Free cash flow |
|---|---|---|---|---|---|---|---|
| 2025 | 2.4B | +5.1% | 770.9M | 32.4% | 1.78 | +23.1% | 2.5B |
| 2024 | 2.3B | -3.9% | 859M | 37.9% | 1.45 | -42.8% | 2.8B |
| 2023 | 2.4B | +5.2% | 1.1B | 48.2% | 2.53 | +2,430.0% | 3B |
| 2022 | 2.2B | — | 42.8M | 1.9% | 0.10 | — | 2.1B |
Dates and earnings per share from the company reports as collected by the data provider; the estimate is the analysts' average before the report. Information, not advice.
Prices by day, week and month
| Period | Opening price | High | Low | Closing price | Change | Volume | Dividend |
|---|---|---|---|---|---|---|---|
| Nov 2026 In progress | 66.97 | 70.37 | 64.84 | 68.77 | +2.37% | 34,685,381 | |
| Oct 2026 | 58.36 | 67.71 | 55.13 | 67.18 | +15.11% | 70,545,600 | |
| Sep 2026 | 61.81 | 64.38 | 57.51 | 58.36 | -4.97% | 68,887,300 | |
| Aug 2026 | 58.26 | 62.46 | 56.36 | 61.41 | +5.10% | 57,654,900 | 0.2350 |
| Jul 2026 | 56.09 | 60.44 | 54.95 | 58.43 | +4.21% | 60,055,600 | |
| Jun 2026 | 55.50 | 57.22 | 51.15 | 56.07 | +0.56% | 83,295,900 | |
| May 2026 | 49.92 | 56.07 | 49.11 | 55.76 | +11.32% | 85,515,700 | 0.2350 |
| Apr 2026 | 47.99 | 50.47 | 46.54 | 50.09 | +4.42% | 62,669,200 | |
| Mar 2026 | 45.87 | 47.98 | 44.73 | 47.97 | +3.81% | 76,385,200 | |
| Feb 2026 | 41.52 | 46.37 | 41.46 | 46.21 | +10.87% | 72,550,100 | 0.2350 |
| 51 older periods: create a free account to see the whole history | |||||||
Prices in USD, adjusted for splits but not for dividends. Weeks run Monday to Friday and months follow the calendar; the change compares each close with the previous period's. Dividends are those whose ex-dividend date falls in the period, per share. Information, not advice.
News
- Royalty Pharma to present at the UBS Global Biopharma Conference (opens in a new tab) 12 Nov 2026 21:15
- Royalty Pharma: Stronger Royalty Growth Supports Further Upside (opens in a new tab) SeekingAlpha · 12 Nov 2026 07:15
- Why Royalty Pharma Investors Could Be the Quiet Winners From Revolution Medicines' Groundbreaking Pancreatic Cancer Drug (opens in a new tab) Motley Fool · 08 Nov 2026 15:35
- How Investors Are Reacting To Royalty Pharma (RPRX) Earnings Beat (opens in a new tab) Simply Wall St. · 06 Nov 2026 22:14
- Royalty Pharma (RPRX) Upgraded to Buy: What Does It Mean for the Stock? (opens in a new tab) Zacks · 06 Nov 2026 16:00
- Royalty Pharma (RPRX) Stock Looks Fully Valued After A 168% Run (opens in a new tab) Simply Wall St. · 06 Nov 2026 08:15
- Can Royalty Pharma (RPRX) Justify Its Price Following A Third Straight Guidance Raise? (opens in a new tab) Simply Wall St. · 06 Nov 2026 01:18
- Citigroup Maintains Buy on Royalty Pharma, Raises Price Target to $78 (opens in a new tab) Benzinga · 05 Nov 2026 17:50
- Royalty Pharma PLC (RPRX) (Q3 2026) Earnings Call Highlights: Raised Guidance, Strong Royalty ... (opens in a new tab) GuruFocus.com · 05 Nov 2026 01:06
- Royalty Pharma plc Q3 2026 Earnings Call Summary (opens in a new tab) Moby · 04 Nov 2026 23:21
- Royalty Pharma Q3 Earnings Call Highlights (opens in a new tab) MarketBeat · 04 Nov 2026 20:14
- Royalty Pharma (RPRX) Q3 2026 Earnings Call Transcript (opens in a new tab) Motley Fool · 04 Nov 2026 19:33
- Royalty Pharma: Unique, Diversified Life Science And Biopharma Pure Play (opens in a new tab) SeekingAlpha · 04 Nov 2026 17:13
- Royalty Pharma PLC (NASDAQ:RPRX) Q3 Portfolio Receipts Beat and 2026 Guidance Raised (opens in a new tab) ChartMill · 04 Nov 2026 13:42
- Compared to Estimates, Royalty Pharma (RPRX) Q3 Earnings: A Look at Key Metrics (opens in a new tab) Zacks · 04 Nov 2026 13:30
Headlines link to the original articles of the publishers shown; Kyvero does not write, check or endorse them. Only the most relevant news about each company is kept. Information, not advice.
Key data
- Previous close
- 68.97 USD
- Market cap
- 39.7B
- Dividend yield
- 1.36%
- 5-year average yield
- 2.16%
- Payout ratio
- 60%
- Last dividend
- 0.2350 USD · 13 Nov 2026
- Next ex-dividend date
- 13 Nov 2026
- Exchange
- NasdaqGS
- Country
- United States
- Sector
- Healthcare
- Industry
- Biotechnology
- Currency
- USD
Dividends
| Ex-dividend date | Per share |
|---|---|
| 14 Aug 2026 | 0.2350 USD |
| 15 May 2026 | 0.2350 USD |
| 20 Feb 2026 | 0.2350 USD |
| 14 Nov 2025 | 0.2200 USD |
| 8 older dividends: create a free account to see them | |
Why this score
| Part of the score | Points | Why |
|---|---|---|
| Yield Dividends per year as a share of today's price. Very high yields count for less: they often signal trouble. | 5.7 / 25 |
|
| Dividend safety Can the company keep paying? The dividend against free cash flow and earnings, plus debt and interest cover. | 15.1 / 25 |
|
| Dividend growth How many years in a row the dividend has risen, and how fast. | 9.2 / 15 |
|
| Quality Return on equity, net margin and how stable the margins are. | 7.4 / 15 |
|
| Valuation Free cash flow yield and the P/E against its sector. | 0.6 / 10 |
|
| Analysts How far the analysts' average target is from today's price. | 2.4 / 5 |
|
- Heavy debt: net debt is 4.8× EBITDA
Income profile: it pays a dividend, so it is scored mainly on the dividend and how safe it is. Based on 95% of the figures (grade A). Warnings take 6 points off.
Warnings take points off and some cap the score. In your account the score also considers how the share fits your portfolio. How the score works
Figures
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| P/E (trailing) | 45.39× | Weak | 30.56× |
| P/E (forward) | 11.75× | Good | 14.16× |
| Price / book | 4.53× | Weak | 3.5× |
| Price / sales | 15.26× | Weak | 3.33× |
| EV / EBITDA | 24.8× | Weak | 11.19× |
| Free cash flow yield | -1.1% | Weak | 2.1% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Gross margin | 99.8% | Good | 54.9% |
| Operating margin | 81.3% | Good | 5.8% |
| Net margin | 25.7% | Good | 1.2% |
| Return on equity | 12.1% | Fair | 4.4% |
| Return on assets | 5.4% | Fair | 2.7% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Revenue growth / year | 2.1% | Weak | 10.1% |
| EPS growth / year | 161.1% | Good | 10.2% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Debt / equity | 0.88× | Fair | 0.4× |
| Net debt / EBITDA | 4.76× | Weak | 1.46× |
| Interest cover | 5.07× | Fair | 2.17× |
| Current ratio | 1.29× | Fair | 2.64× |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Payout of earnings | 60.5% | Fair | 0% |
| Payout of free cash flow (3 years) | 13.5% | Good | — |
| Dividend growth / year | 6.7% | Good | 6.5% |
| Years of rising dividends | 4 | Fair | 1.5 |
The reading follows general rules of thumb and each sector has its own norms: compare with the sector median when it is shown. Information, not advice.
Similar shares
Follow RPRX and get alerts
Create a free account to add it to your watchlist, set a price alert, see how it fits your portfolio and track your dividends.